Drug intelligence / Profile preview

influenza virus vaccine, quadrivalent, split virus

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Quadrivalent split influenza virus vaccine is an inactivated vaccine prepared from influenza viruses propagated in embryonated hens' eggs. It contains four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The viruses are inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate. It is administered via intramuscular injection for the prevention of seasonal influenza.

Brand names: FluLaval QuadrivalentFluzone Quadrivalent
Other names: quadrivalent split influenza virus vaccineIIV4IIV-4IIV 4Influenza Vaccine, Quadrivalent

Beyond the preview

Go deeper on influenza virus vaccine, quadrivalent, split virus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza virus vaccine, quadrivalent, split virus.

Explore the full profile